158 related articles for article (PubMed ID: 38423708)
1. Duvelisib: A comprehensive profile.
Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
[TBL] [Abstract][Full Text] [Related]
2. Duvelisib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
[TBL] [Abstract][Full Text] [Related]
3. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Patel K; Danilov AV; Pagel JM
Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
[TBL] [Abstract][Full Text] [Related]
4. Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
[TBL] [Abstract][Full Text] [Related]
5. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Nikolaenko L; Liu T; Danilov AV
Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
[No Abstract] [Full Text] [Related]
6. [New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma].
Fornero L; Lamure S
Bull Cancer; 2021 Oct; 108(10):906-907. PubMed ID: 34607678
[No Abstract] [Full Text] [Related]
7. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu HV; Jain N; Gandhi V
Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
[TBL] [Abstract][Full Text] [Related]
8. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Makita S; Ota S; Mishima Y; Usuki K; Ennishi D; Yanada M; Fukuhara N; Yamamoto R; Takamine A; Nohara G; Izutsu K
Int J Hematol; 2024 Feb; 119(2):156-163. PubMed ID: 38150138
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
10. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
11. Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases.
Rodrigues DA; Sagrillo FS; Fraga CAM
Pharmaceuticals (Basel); 2019 May; 12(2):. PubMed ID: 31064155
[TBL] [Abstract][Full Text] [Related]
12. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
Patel VM; Balakrishnan K; Douglas M; Tibbitts T; Xu EY; Kutok JL; Ayers M; Sarkar A; Guerrieri R; Wierda WG; O'Brien S; Jain N; Stern HM; Gandhi V
Leukemia; 2017 Sep; 31(9):1872-1881. PubMed ID: 28017967
[TBL] [Abstract][Full Text] [Related]
13. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
[TBL] [Abstract][Full Text] [Related]
14. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
15. Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.
Shah A; Barrientos JC
Onco Targets Ther; 2021; 14():2109-2119. PubMed ID: 33790574
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, spectroscopic and computational studies on hydrogen bonded charge transfer complex of duvelisib with chloranilic acid: Application to development of novel 96-microwell spectrophotometric assay.
Darwish IA; Almehizia AA; Sayed AY; Khalil NY; Alzoman NZ; Darwish HW
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120287. PubMed ID: 34455386
[TBL] [Abstract][Full Text] [Related]
17. A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats.
Sayed AY; Khalil NY; Almomen A; Alzoman NZ; Almehizia AA; Darwish IA
Drug Des Devel Ther; 2021; 15():2667-2677. PubMed ID: 34188446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
19. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
Iannello A; Vitale N; Coma S; Arruga F; Chadburn A; Di Napoli A; Laudanna C; Allan JN; Furman RR; Pachter JA; Deaglio S; Vaisitti T
Blood; 2021 Jun; 137(24):3378-3389. PubMed ID: 33786583
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
Davids MS; Kuss BJ; Hillmen P; Montillo M; Moreno C; Essell J; Lamanna N; Nagy Z; Tam CS; Stilgenbauer S; Ghia P; Delgado J; Lustgarten S; Weaver DT; Youssoufian H; Jäger U
Clin Cancer Res; 2020 May; 26(9):2096-2103. PubMed ID: 31964785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
